Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials

Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials

Background: Triptans are the first-line option for the acute treatment of migraine attacks; however, triptans are contraindicated in people with certain underlying cardiovascular risk factors and are associated with inadequate efficacy or poor tolerability in some individuals. Ubrogepant is an oral...

Full description

Bibliographic Details
Main Authors: Dodick, D.W (Author), Lateiner, J.E (Author), Lipton, R.B (Author), Revicki, D.A (Author), Shewale, A.R (Author), Singh, R.B.H (Author), Zhao, S. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
ACHIEVE
Calcitonin gene–related peptide receptor antagonist
Functionality
Migraine
Patient-reported outcomes
Satisfaction
Triptan
Online Access:View Fulltext in Publisher

Similar Items

Similar Items